ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1913

Health Literacy and Disease, Clinical, Functional and Management Outcomes in Inflammatory Arthritis: A Systematic Literature Review

Mrinalini Dey1, Shyam Budhathoki2, Sofia Ramiro3, Kaleb Michaud4, Helen Elwell5, Sam Norton6, Maya H. Buch7, Andrew Cope1, Richard Osborne8, James Galloway9 and Elena Nikiphorou1, 1King's College London, London, United Kingdom, 2Imperial College London, London, United Kingdom, 3Leiden University Medical Center, Bunde, Netherlands, 4University of Nebraska Medical Center, Omaha, NE, 5British Medical Association, London, United Kingdom, 6King's College London, London, England, United Kingdom, 7Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 8Swinburne University of Technology, Swinburne, Australia, 9Centre for Rheumatic Diseases, King's College London, London, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Education, education, patient, health behaviors, Health policy, quality of life

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Healthcare Disparities in Rheumatology Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Health literacy (HL) is a key social determinant of health in inflammatory arthritis (IA), including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, as it can determine engagement in diagnostic, treatment and self-management. We aimed to conduct a systematic literature review (SLR) to i) summarise associations between HL and IA outcomes; iii) inform management in IA; ii) identify areas for further research.

Methods: This SLR was registered on PROSPERO (CRD42024511354). Inclusion criteria were adults (≥18 years) with IA; studies assessing HL or interventions targeting HL; observational and qualitative studies, randomised controlled trials; English-language articles.

A comprehensive search was performed in February 2024, with MeSH headings and keywords for HL and IA, in MEDLINE, Scopus, Cochrane Library, Health Technology Assessment and PsycINFO, with no time restriction. HL measures and outcomes were not defined, to ensure capture of all potentially relevant articles.

Data were extracted on demographics, HL assessment and relevant outcomes such as (but not limited to) disease activity, quality of life, function and healthcare utilisation. Outcomes were then grouped into core themes.

Results: Of 3087 identified articles (following de-duplication), 29 were included, comprising: 22 cross-sectional studies; two randomised controlled trials; two prospective cohort studies; one case-control study; one retrospective cohort study; one qualitative study. The total cohort comprised 16402 individuals (75% female), with a mean age of 57.5 years (SD 9.6). Ethnicity was reported in 13 studies; 66% of patients were Caucasian. 89% had rheumatoid arthritis, 4% axial spondyloarthritis, 3% psoriatic arthritis and 4% unspecified IA (Table 1).

Measures of HL included: Test of Functional Health Literacy in Adults (short and long form; n=13); Single Item Literacy Screener (n=10); Rapid Estimate of Adult Literacy in Medicine (n=6); Health Literacy Questionnaire (n=2).

Identified themes included disease activity, patient-reported outcomes (PROs), healthcare utilisation and medication history. Key findings are in Figure 1.

Meta-analysis was deemed inappropriate due to marked heterogeneity of exposure and outcome measures. Outcomes were grouped based on themes. Overall, low HL was associated with worse disease activity (across a cohort of n=816 patients); greater disability (n=6678); higher depression and anxiety (n=958); higher cognitive, emotional and physical fatigue (n=708); poorer medication adherence (n=6051); lower internet access and confidence with remote consultations (n=832); increased healthcare utilisation (n=123); decreased understanding of health information and shared decision-making.

Conclusion: This is the first SLR to comprehensively synthesise the extensive outcomes associated with HL in people with IA, including increased disease activity, worse PROs, greater healthcare utilisation and decreased access to medication and care.

Our findings may be used to inform policy and resource allocation, and improve access and quality of care in IA, particularly among those patients with lower HL.

Supporting image 1

Table 1: Demographics of included study cohorts.
axSpa: axial spondyloarthritis. AYA: adolescents and young adults. IA: inflammatory arthritis. PsA: psoriatic arthritis. RA: rheumatoid arthritis. RCT: randomised controlled trial. * denotes cohorts from the same study.

Supporting image 2

Figure 1: Key associations between health literacy (HL) and outcomes in inflammatory arthritis.
eHEALS: eHealth Literacy Scale. HELP: Health Education Literacy. HLQ: Health Literacy Questionnaire. REALM: Rapid Estimate of Adult Literacy in Medicine. RLG: Rheumatology Literacy Guide. SILS: Single Item Literacy Screener. STOFHLA: Short Test of Functional Health Literacy in Adults. TOFHLA: Test of Functional Health Literacy in Adults. DMARD: disease-modifying anti-rheumatic drug. bDMARD: biologic DMARD. csDMARD: conventional synthetic DMARD. DAS: disease activity score. DAS28: disease activity score 28- joints. HAQ: Health Assessment Questionnaire. MDHAQ: Multi-Dimensional Health Assessment Questionnaire. HAD: Hospital Anxiety and Depression scale. OR: odds ratio.


Disclosures: M. Dey: None; S. Budhathoki: None; S. Ramiro: AbbVie, 1, 2, 5, 6, Alfasigma, 1, 2, 5, Galapagos, 1, 2, 5, Lilly, 1, 2, 6, MSD, 2, 5, 6, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, UCB, 1, 2, 5, 6; K. Michaud: None; H. Elwell: None; S. Norton: None; M. Buch: AbbVie, 2, 6, Arxx Therapeutics, 2, Boehringer Ingelheim, 6, CESAS Medical, 6, Galapagos, 2, 6, Gilead, 2, 5, 6, Medistream, 6, Pfizer, 2, 6; A. Cope: AbbVie, 6, Bristol-Myers Squibb, 2, 5, 6, GSK/Galvini, 12, Data monitoring committee, Janssen, 2, 5, UCB, 2, 5; R. Osborne: None; J. Galloway: AbbVie, 6, AstraZeneca, 5, Galapagos, 2, 6, Janssen, 2, 5, 6, Lilly, 2, 6, Pfizer, 2, 5, 6, UCB, 6; E. Nikiphorou: AbbVie, 1, 6, Alfasigma, 1, 6, Fresenius Kabi, 1, 6, Galapagos, 1, 6, Gilead, 1, 6, Lilly, 1, 5, 6, Pfizer, 1, 5, 6, UCB, 1, 6.

To cite this abstract in AMA style:

Dey M, Budhathoki S, Ramiro S, Michaud K, Elwell H, Norton S, Buch M, Cope A, Osborne R, Galloway J, Nikiphorou E. Health Literacy and Disease, Clinical, Functional and Management Outcomes in Inflammatory Arthritis: A Systematic Literature Review [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/health-literacy-and-disease-clinical-functional-and-management-outcomes-in-inflammatory-arthritis-a-systematic-literature-review/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-literacy-and-disease-clinical-functional-and-management-outcomes-in-inflammatory-arthritis-a-systematic-literature-review/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology